

DAFTAR PUSTAKA

- [1] F. Bray, M. Laversanne, E. Weiderpass, and I. Soerjomataram, “The ever-increasing importance of cancer as a leading cause of premature death worldwide,” *Cancer*, vol. 127, no. 16, pp. 3029–3030, Aug. 2021, doi: 10.1002/cncr.33587.
- [2] F. Bray *et al.*, “Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries,” *CA. Cancer J. Clin.*, vol. 74, no. 3, pp. 229–263, May 2024, doi: 10.3322/caac.21834.
- [3] “Rectal Cancer Treatment - NCI.” Accessed: Jan. 03, 2025. [Online]. Available: <https://www.cancer.gov/types/colorectal/patient/rectal-treatment-pdq>
- [4] D. S. Keller, M. Berho, R. O. Perez, S. D. Wexner, and M. Chand, “The multidisciplinary management of rectal cancer,” *Nat. Rev. Gastroenterol. Hepatol.*, vol. 17, no. 7, pp. 414–429, July 2020, doi: 10.1038/s41575-020-0275-y.
- [5] G. Feeney *et al.*, “Neoadjuvant radiotherapy for rectal cancer management,” *World J. Gastroenterol.*, vol. 25, no. 33, pp. 4850–4869, Sept. 2019, doi: 10.3748/wjg.v25.i33.4850.
- [6] S. Yamada *et al.*, “Carbon-ion Radiotherapy for Colorectal Cancer,” *J. Anus Rectum Colon*, vol. 5, no. 2, pp. 113–120, Apr. 2021, doi: 10.23922/jarc.2020-082.
- [7] W. Tinganelli and M. Durante, “Carbon Ion Radiobiology,” *Cancers*, vol. 12, no. 10, p. 3022, Oct. 2020, doi: 10.3390/cancers12103022.
- [8] “What is Carbon Ion Radiotherapy? - QST Hospital (Former NIRS Hospital).” Accessed: Aug. 26, 2025. [Online]. Available: <https://hospital.qst.go.jp/en/patients/radiotherapy.html>
- [9] K. Takada, H. Kumada, A. Matsumura, H. Sakurai, and T. Sakae, “Computational evaluation of dose distribution for BNCT treatment combined with X-ray therapy or proton beam therapy,” *Appl. Radiat. Isot.*, vol. 165, p. 109295, Nov. 2020, doi: 10.1016/j.apradiso.2020.109295.
- [10] H. Tsujii and T. Kamada, “A Review of Update Clinical Results of Carbon Ion Radiotherapy,” *Jpn. J. Clin. Oncol.*, vol. 42, no. 8, pp. 670–685, Aug. 2012, doi: 10.1093/jjco/hys104.
- [11] S. E. Combs *et al.*, “Heidelberg Ion Therapy Center (HIT): Initial clinical experience in the first 80 patients,” *Acta Oncol.*, vol. 49, no. 7, pp. 1132–1140, Oct. 2010, doi: 10.3109/0284186X.2010.498432.
- [12] E. Orlandi *et al.*, “The Role of Carbon Ion Therapy in the Changing Oncology Landscape—A Narrative Review of the Literature and the Decade of Carbon Ion Experience at the Italian National Center for Oncological Hadrontherapy,” *Cancers*, vol. 15, no. 20, p. 5068, Oct. 2023, doi: 10.3390/cancers15205068.
- [13] Y. Li *et al.*, “Flourish of Proton and Carbon Ion Radiotherapy in China,” *Front. Oncol.*, vol. 12, p. 819905, Feb. 2022, doi: 10.3389/fonc.2022.819905.



- [14] A. Bin Sumaida, N. M. Shanbhag, K. AlKaabi, and K. Balaraj, “Cost-Effectiveness of Carbon Ion Radiotherapy in Oncology: A Systematic Review,” *Cureus*, May 2025, doi: 10.7759/cureus.84008.
- [15] W. A. Nugra, A. W. Harto dan Y. Sardjono, Optimasi Arah Penyinaran Berdasarkan Dosis dan Waktu Iradiasi untuk Terapi Proton pada Kanker Rektum Menggunakan Program PHITS Versi 3.33, Universitas Gadjah Mada, Yogyakarta, 2024.
- [16] C.-G. Pang *et al.*, “Monte Carlo simulation of carbon ion radiotherapy for the human eye,” *Chin. Phys. C*, vol. 39, no. 1, p. 018201, Jan. 2015, doi: 10.1088/1674-1137/39/1/018201.
- [17] H.-B. Shin *et al.*, “Dosimetric comparison of robust angles in carbon-ion radiation therapy for prostate cancer,” *Front. Oncol.*, vol. 13, p. 1054693, Feb. 2023, doi: 10.3389/fonc.2023.1054693.
- [18] X. Cai *et al.*, “The role of carbon ion radiotherapy for unresectable locally recurrent rectal cancer: a single institutional experience,” *Radiat. Oncol.*, vol. 15, no. 1, p. 209, Dec. 2020, doi: 10.1186/s13014-020-01653-w.
- [19] S. Marecik, J. Park, and L. M. Prasad, “Rectal Anatomy: Clinical Perspective,” in *Rectal Cancer*, G. J. Chang, Ed., Cham: Springer International Publishing, 2018, pp. 1–23. doi: 10.1007/978-3-319-16384-0_1.
- [20] “Genetics of Colorectal Cancer (PDQ®) - NCI.” Accessed: Aug. 20, 2025. [Online]. Available: <https://www.cancer.gov/types/colorectal/hp/colorectal-genetics-pdq>
- [21] E. Dekker, P. J. Tanis, J. L. A. Vleugels, P. M. Kasi, and M. B. Wallace, “Colorectal cancer,” *The Lancet*, vol. 394, no. 10207, pp. 1467–1480, Oct. 2019, doi: 10.1016/S0140-6736(19)32319-0.
- [22] I. Mármol, C. Sánchez-de-Diego, A. Pradilla Dieste, E. Cerrada, and M. Rodríguez Yoldi, “Colorectal Carcinoma: A General Overview and Future Perspectives in Colorectal Cancer,” *Int. J. Mol. Sci.*, vol. 18, no. 1, p. 197, Jan. 2017, doi: 10.3390/ijms18010197.
- [23] S. Winawer, “Colorectal cancer screening and surveillance: Clinical guidelines and rationale?Update based on new evidence,” *Gastroenterology*, vol. 124, no. 2, pp. 544–560, Feb. 2003, doi: 10.1053/gast.2003.50044.
- [24] T. Muto, H. J. R. Bussey, and B. C. Morson, “The evolution of cancer of the colon and rectum,” *Cancer*, vol. 36, no. 6, pp. 2251–2270, Dec. 1975, doi: 10.1002/cncr.2820360944.
- [25] C. Mattiuzzi, F. Sanchis-Gomar, and G. Lippi, “Concise update on colorectal cancer epidemiology,” *Ann. Transl. Med.*, vol. 7, no. 21, pp. 609–609, Nov. 2019, doi: 10.21037/atm.2019.07.91.
- [26] S. De Pietro *et al.*, “The role of MRI in radiotherapy planning: a narrative review ‘from head to toe,’” *Insights Imaging*, vol. 15, no. 1, p. 255, Oct. 2024, doi: 10.1186/s13244-024-01799-1.
- [27] E. Bompou, A. Vassiou, I. Baloyiannis, K. Perivoliotis, I. Fezoulidis, and G. Tzovaras, “Comparative evaluation of CT and MRI in the preoperative staging of colon cancer,” *Sci. Rep.*, vol. 14, no. 1, p. 17145, July 2024, doi: 10.1038/s41598-024-68147-7.



- [28] S. V. R. C. Wolberink, R. G. H. Beets-Tan, D. F. M. De Haas-Kock, E. J. Van De Jagt, M. M. Span, and T. Wiggers, "Multislice CT as a Primary Screening Tool for the Prediction of an Involved Mesorectal Fascia and Distant Metastases in Primary Rectal Cancer: A Multicenter Study," *Dis. Colon Rectum*, vol. 52, no. 5, pp. 928–934, May 2009, doi: 10.1007/DCR.0b013e318194f923.
- [29] J. Brierley, M. K. Gospodarowicz, C. Wittekind, and J. Brierley, *TNM Classification of Malignant Tumours*, 8th ed. in Uicc. Chichester: John Wiley & Sons, Incorporated, 2017.
- [30] R. Rami-Porta, "The TNM classification of lung cancer—a historic perspective," *J. Thorac. Dis.*, vol. 16, no. 11, pp. 8053–8067, Nov. 2024, doi: 10.21037/jtd-24-1212.
- [31] C. Klessen, P. Rogalla, and M. Taupitz, "Local staging of rectal cancer: the current role of MRI," *Eur. Radiol.*, vol. 17, no. 2, pp. 379–389, Feb. 2007, doi: 10.1007/s00330-006-0388-x.
- [32] A. Y. Kim, "Imaging Diagnosis of Colorectal Cancer," *J. Korean Med. Assoc.*, vol. 53, no. 7, p. 562, 2010, doi: 10.5124/jkma.2010.53.7.562.
- [33] F. H. Attix, *Introduction to radiological physics and radiation dosimetry*. in Physics textbook. Weinheim: Wiley-VCH, 2004.
- [34] E. B. Podgorsak, *Radiation Physics for Medical Physicists 3rd Ed*. Springer, 2016.
- [35] J. E. Turner, *Atoms, radiation, and radiation protection*, 3., Completely revised and enl. Ed., 2. repr. in Physics textbook. Weinheim: Wiley-VCH, 2010.
- [36] Nanda Karmaker *et al.*, "Fundamental characteristics and application of radiation," *GSC Adv. Res. Rev.*, vol. 7, no. 1, pp. 064–072, Apr. 2021, doi: 10.30574/gscarr.2021.7.1.0043.
- [37] S. Baatout, Ed., *Radiobiology Textbook*. Cham: Springer International Publishing, 2023. doi: 10.1007/978-3-031-18810-7.
- [38] N. Foray, C. F. Arlett, and E. P. Malaise, "Radiation-induced DNA double-strand breaks and the radiosensitivity of human cells: A closer look," *Biochimie*, vol. 79, no. 9–10, pp. 567–575, Oct. 1997, doi: 10.1016/S0300-9084(97)82005-6.
- [39] Advanced Materials Research Group, Faculty of Engineering, University of Nottingham, Nottingham NG7 2RD, United Kingdom *et al.*, "The Use of Biomaterials in Internal Radiation Therapy," *Recent Prog. Mater.*, vol. 2, no. 2, pp. 1–34, May 2020, doi: 10.21926/rpm.2002012.
- [40] J.-R. Liu, Y.-X. Liu, and Y.-N. Wang, "A comprehensive study on the electron cyclotron resonance effect in a weakly magnetized capacitively coupled RF plasma: experiment, simulation and modeling," *Plasma Sources Sci. Technol.*, vol. 32, no. 4, p. 044004, Apr. 2023, doi: 10.1088/1361-6595/acc685.
- [41] C. H. Lee, B.-H. Oh, D.-S. Chang, and S.-C. Jeong, "Carbon beam extraction with 14.5 GHz electron cyclotron resonance ion source at Korea Atomic Energy Research Institute," *Rev. Sci. Instrum.*, vol. 85, no. 2, p. 02A903, Feb. 2014, doi: 10.1063/1.4825077.



- [42] O. Mohamad, H. Makishima, and T. Kamada, "Evolution of Carbon Ion Radiotherapy at the National Institute of Radiological Sciences in Japan," *Cancers*, vol. 10, no. 3, p. 66, Mar. 2018, doi: 10.3390/cancers10030066.
- [43] G.-B. Kim *et al.*, "Korea Heavy Ion Medical Accelerator Project," *Proc. 7th Int Part. Accel. Conf*, vol. IPAC2016, p. 5 pages, 1.083 MB, 2016, doi: 10.18429/JACOW-IPAC2016-FRXAA01.
- [44] M. Xiao, B. Liu, J. Peng, M. Li, and S. Xie, "Comparison of cyclotron and synchrotron in particle therapy," *Vis. Cancer Med.*, vol. 5, p. 7, 2024, doi: 10.1051/vcm/2024008.
- [45] X. Zhang, "Lattice Design of a Carbon-Ion Synchrotron based on Double-Bend Achromat Lens," 2020, *arXiv*. doi: 10.48550/ARXIV.2007.11787.
- [46] K. Noda, "Beam Delivery Method for Carbon-ion Radiotherapy with the Heavy-ion Medical Accelerator in Chiba," *Int. J. Part. Ther.*, vol. 2, no. 4, pp. 481–489, Mar. 2016, doi: 10.14338/IJPT-15-00041.1.
- [47] T. Kanai *et al.*, "Biophysical characteristics of HIMAC clinical irradiation system for heavy-ion radiation therapy," *Int. J. Radiat. Oncol.*, vol. 44, no. 1, pp. 201–210, Apr. 1999, doi: 10.1016/S0360-3016(98)00544-6.
- [48] K. Noda *et al.*, "New treatment facility for heavy-ion cancer therapy at HIMAC," *Nucl. Instrum. Methods Phys. Res. Sect. B Beam Interact. Mater. At.*, vol. 266, no. 10, pp. 2182–2185, May 2008, doi: 10.1016/j.nimb.2008.02.075.
- [49] T. Furukawa *et al.*, "Design study of a rotating gantry for the HIMAC new treatment facility," *Nucl. Instrum. Methods Phys. Res. Sect. B Beam Interact. Mater. At.*, vol. 266, no. 10, pp. 2186–2189, May 2008, doi: 10.1016/j.nimb.2008.02.078.
- [50] O. Mohamad, H. Makishima, and T. Kamada, "Evolution of Carbon Ion Radiotherapy at the National Institute of Radiological Sciences in Japan," *Cancers*, vol. 10, no. 3, p. 66, Mar. 2018, doi: 10.3390/cancers10030066.
- [51] "Overview of the Heavy-Ion Medical Accelerator in Chiba (HIMAC) Practices," in *Carbon-Ion Radiotherapy*, Tokyo: Springer Japan, 2014, pp. 17–22. doi: 10.1007/978-4-431-54457-9_3.
- [52] Y. A. Abdulla, Y. M. Amin, and H. B. Khoo, "Determination of percentage depth dose for 6 and 10 MV x-rays using Ge-doped optical fibre and TLD-100," *J. Radiol. Prot.*, vol. 22, no. 4, pp. 417–421, Dec. 2002, doi: 10.1088/0952-4746/22/4/306.
- [53] M. B. Laksono, S. Wardaya, and W. S. Budi, "STUDI KOMPARASI METODE PERCENTAGE DEPTH DOSE (PDD) DAN TISSUE PHANTOM RATIO (TPR) UNTUK MENENTUKAN INDEK KUALITAS BERKAS ENERGI 6 MV DAN 10 MV PADA PESAWAT LINAC," vol. 18, no. 1.
- [54] International Commission on Radiological Protection, Ed., *Radiological protection in ion beam radiotherapy*. in *Annals of the ICRP*, no. 43.2014,4. St. Louis, Md.: Elsevier, 2014.
- [55] E. Fokas, G. Kraft, H. An, and R. Engenhart-Cabillic, "Ion beam radiobiology and cancer: Time to update ourselves," *Biochim. Biophys. Acta BBA - Rev. Cancer*, vol. 1796, no. 2, pp. 216–229, Dec. 2009, doi: 10.1016/j.bbcan.2009.07.005.



- [56] T. F. DeLaney, A. V. Trofimov, M. Engelsman, and H. D. Suit, “Advanced-Technology Radiation Therapy in the Management of Bone and Soft Tissue Sarcomas”.
- [57] L. Kristensen *et al.*, “Spread-out Bragg peak FLASH: quantifying normal tissue toxicity in a murine model,” *Front. Oncol.*, vol. 14, p. 1427667, July 2024, doi: 10.3389/fonc.2024.1427667.
- [58] C. E. Hill-Kayser, S. Both, and Z. Tochner, “Proton Therapy: Ever Shifting Sands and the Opportunities and Obligations within,” *Front. Oncol.*, vol. 1, 2011, doi: 10.3389/fonc.2011.00024.
- [59] W. Newhauser, “International Commission on Radiation Units and Measurements Report 78: Prescribing, Recording and Reporting Proton-beam Therapy,” *Radiat. Prot. Dosimetry*, vol. 133, no. 1, pp. 60–62, Jan. 2009, doi: 10.1093/rpd/ncp005.
- [60] D. J. Thomas, “ICRU report 85: fundamental quantities and units for ionizing radiation,” *Radiat. Prot. Dosimetry*, vol. 150, no. 4, pp. 550–552, July 2012, doi: 10.1093/rpd/ncs077.
- [61] F. Koosha, M. Ahmadikamalabadi, and M. Mohammadi, “Review of Recent Improvements in Carbon Ion Radiation Therapy in the Treatment of Glioblastoma,” *Adv. Radiat. Oncol.*, vol. 9, no. 5, p. 101465, May 2024, doi: 10.1016/j.adro.2024.101465.
- [62] D. MacManus, D. Bell, and A. Murphy, “Linear energy transfer,” in *Radiopaedia.org*, Radiopaedia.org, 2020. doi: 10.53347/rID-74681.
- [63] O. Mohamad *et al.*, “Carbon Ion Radiotherapy: A Review of Clinical Experiences and Preclinical Research, with an Emphasis on DNA Damage/Repair,” *Cancers*, vol. 9, no. 6, p. 66, June 2017, doi: 10.3390/cancers9060066.
- [64] F. Tommasino, E. Scifoni, and M. Durante, “New Ions for Therapy,” *Int. J. Part. Ther.*, vol. 2, no. 3, pp. 428–438, 2016, doi: 10.14338/IJPT-15-00027.1.
- [65] E. J. Hall and A. J. Giaccia, *Radiobiology for the radiologist*, 7th ed. Philadelphia, Pa. Londo: Wolters Kluwer Lippincott Williams & Wilkins, 2012.
- [66] Y. Huang *et al.*, “The Impacts of Different Types of Radiation on the CRT and PDL1 Expression in Tumor Cells Under Normoxia and Hypoxia,” *Front. Oncol.*, vol. 10, p. 1610, Aug. 2020, doi: 10.3389/fonc.2020.01610.
- [67] O. Sokol and M. Durante, “Carbon Ions for Hypoxic Tumors: Are We Making the Most of Them?,” *Cancers*, vol. 15, no. 18, p. 4494, Sept. 2023, doi: 10.3390/cancers15184494.
- [68] D. Wang, “A critical appraisal of the clinical utility of proton therapy in oncology,” *Med. Devices Evid. Res.*, p. 439, Oct. 2015, doi: 10.2147/MDER.S65594.
- [69] R. Pidikiti *et al.*, “Commissioning of the world’s first compact pencil-beam scanning proton therapy system,” *J. Appl. Clin. Med. Phys.*, vol. 19, no. 1, pp. 94–105, Jan. 2018, doi: 10.1002/acm2.12225.
- [70] F. Bourhaleb, A. Attili, and G. Russo, “Monte Carlo Simulations for Beam Delivery Line Design in Radiation Therapy with Heavy Ion Beams,” in



- Applications of Monte Carlo Methods in Biology, Medicine and Other Fields of Science*, C. J. Mode, Ed., InTech, 2011. doi: 10.5772/15883.
- [71] E. M. Rosen, S. Fan, S. Rockwell, and I. D. Goldberg, “The molecular and cellular basis of radiosensitivity: implications for understanding how normal tissues and tumors respond to therapeutic radiation,” *Cancer Invest.*, vol. 17, no. 1, pp. 56–72, 1999.
- [72] J. Thoms and R. G. Bristow, “DNA Repair Targeting and Radiotherapy: A Focus on the Therapeutic Ratio,” *Semin. Radiat. Oncol.*, vol. 20, no. 4, pp. 217–222, Oct. 2010, doi: 10.1016/j.semradonc.2010.06.003.
- [73] N. G. Burnet, “Defining the tumour and target volumes for radiotherapy,” *Cancer Imaging*, vol. 4, no. 2, pp. 153–161, 2004, doi: 10.1102/1470-7330.2004.0054.
- [74] A. Barrett and J. Dobbs, Eds., *Practical radiotherapy planning*, 4. ed. London: Hodder Arnold, 2009.
- [75] D. Jones, “ICRU Report 50—Prescribing, Recording and Reporting Photon Beam Therapy,” *Med. Phys.*, vol. 21, no. 6, pp. 833–834, June 1994, doi: 10.1118/1.597396.
- [76] ICRU, “ICRU Report 62: Prescribing, Recording and Reporting Photon Beam Therapy (Supplement to ICRU Report 50).”
- [77] L. Beaton, S. Bandula, M. N. Gaze, and R. A. Sharma, “How rapid advances in imaging are defining the future of precision radiation oncology,” *Br. J. Cancer*, vol. 120, no. 8, pp. 779–790, Apr. 2019, doi: 10.1038/s41416-019-0412-y.
- [78] J. Wan *et al.*, “TORCH-R trial protocol: hypofractionated radiotherapy combined with chemotherapy and toripalimab for locally recurrent rectal cancer: a prospective, single-arm, two-cohort, phase II trial,” *Front. Oncol.*, vol. 13, p. 1304767, Nov. 2023, doi: 10.3389/fonc.2023.1304767.
- [79] Y. Yang *et al.*, “Automatic segmentation of the clinical target volume and organs at risk for rectal cancer radiotherapy using structure-contextual representations based on 3D high-resolution network,” *Biomed. Signal Process. Control*, vol. 73, p. 103362, Mar. 2022, doi: 10.1016/j.bspc.2021.103362.
- [80] B. H. Bakkal and O. Elmas, “Dosimetric comparison of organs at risk in 5 different radiotherapy plans in patients with preoperatively irradiated rectal cancer,” *Medicine (Baltimore)*, vol. 100, no. 1, p. e24266, Jan. 2021, doi: 10.1097/MD.00000000000024266.
- [81] E. B. Podgorsak, *Radiation Oncology Physics*: Vienna: IAEA, 2005.
- [82] F. M. Khan and J. P. Gibbons, *Khan’s the physics of radiation therapy*, 5th edition. Philadelphia, PA: Lippincott Williams & Wilkins, 2014.
- [83] Internationale Atomenergie-Organisation and International Commission on Radiation Units and Measurements, Eds., *Relative biological effectiveness in Ion Beam Therapy*. in Technical reports series / International Atomic Energy Agency, no. 461. Vienna: International Atomic Energy Agency, 2008.
- [84] O. N. Vassiliev, *Monte Carlo Methods for Radiation Transport*. in Biological and Medical Physics, Biomedical Engineering. Cham: Springer International Publishing, 2017. doi: 10.1007/978-3-319-44141-2.



- [85] H. Iwase, K. Niita, and T. Nakamura, "Development of General-Purpose Particle and Heavy Ion Transport Monte Carlo Code," *J. Nucl. Sci. Technol.*, vol. 39, no. 11, pp. 1142–1151, Nov. 2002, doi: 10.1080/18811248.2002.9715305.
- [86] T. Sato *et al.*, "Overview of the PHITS code and its application to medical physics," *Prog. Nucl. Sci. Technol.*, vol. 4, pp. 879–882, 2014, doi: 10.15669/pnst.4.879.
- [87] S. Pak and F. A. Cucinotta, "Comparison between PHITS and GEANT4 Simulations of the Heavy Ion Beams at the BEVALAC at LBNL and the Booster Accelerator at BNL," *Life Sci. Space Res.*, vol. 29, pp. 38–45, May 2021, doi: 10.1016/j.lssr.2021.03.002.
- [88] T. Smith, N. Petoussi-Henss, and M. Zankl, "Comparison of internal radiation doses estimated by MIRD and voxel techniques for a 'family' of phantoms," *Eur. J. Nucl. Med.*, vol. 27, no. 9, pp. 1387–1398, Sept. 2000, doi: 10.1007/s002590000294.
- [89] D. Krstić and D. Nikezić, "Input files with ORNL—mathematical phantoms of the human body for MCNP-4B," *Comput. Phys. Commun.*, vol. 176, no. 1, pp. 33–37, Jan. 2007, doi: 10.1016/j.cpc.2006.06.016.
- [90] C. H. Kim *et al.*, *Adult mesh-type reference computational phantoms*. in *Annals of the ICRP*, no. volume 49, no. 3 (2020). London: SAGE, 2020.
- [91] R. M. Jr, C. Gesh, R. Pagh, R. Rucker, and R. W. Iii, "Compendium of Material Composition Data for Radiation Transport Modeling," 2011.
- [92] S. Yamada *et al.*, "Carbon Ion Radiotherapy for Locally Recurrent Rectal Cancer of Patients with Prior Pelvic Irradiation," *Ann. Surg. Oncol.*, vol. 29, no. 1, pp. 99–106, Jan. 2022, doi: 10.1245/s10434-021-10876-4.
- [93] Kenji Sato *et al.*, "Heavy Ion Medical Accelerator in Chiba (HIMAC)," *Part. Accel.*, vol. 33, pp. 147–152, 1990, doi: 10.1080/1071441950170102.
- [94] J. Kim, J. M. Park, and H.-G. Wu, "Carbon Ion Therapy: A Review of an Advanced Technology," *Prog. Med. Phys.*, vol. 31, no. 3, pp. 71–80, Sept. 2020, doi: 10.14316/pmp.2020.31.3.71.
- [95] J. Liermann, M. Shinoto, M. Syed, J. Debus, K. Herfarth, and P. Naumann, "Carbon ion radiotherapy in pancreatic cancer: A review of clinical data," *Radiother. Oncol.*, vol. 147, pp. 145–150, June 2020, doi: 10.1016/j.radonc.2020.05.012.
- [96] International Commission on Radiation Units and Measurements (ICRU), "ICRU Report 93: Prescribing, Recording, and Reporting Light Ion Beam Therapy," *J. ICRU*, vol. 16, no. 1–2, 2016.
- [97] S. Bisello *et al.*, "Dose–Volume Constraints for oRganS At risk In Radiotherapy (CORSAIR): An 'All-in-One' Multicenter–Multidisciplinary Practical Summary," *Curr. Oncol.*, vol. 29, no. 10, pp. 7021–7050, Sept. 2022, doi: 10.3390/currncol29100552.
- [98] A. Mahmoudi, G. Geraily, A. Shirazi, and T. Hadisi Nia, "Penumbra reduction technique and factors affecting it in radiotherapy machines – Review study," *Radiat. Phys. Chem.*, vol. 157, pp. 22–27, Apr. 2019, doi: 10.1016/j.radphyschem.2018.12.016.



- [99] G. D. Patatoukas, P. Kalavrezos, I. Seimenis, M. Dilvoi, E. Efstathopoulos, and K. Platoni, “Determination of beam profile characteristics in radiation therapy using different dosimetric set ups”.

